Latanoprost 0.005% versus bimatoprost 0.03% in primary open-angle glaucoma patients

Konstas, Anastasios G. P.; Katsimbris, John M.; Lallos, Nikolaos; Boukaras, George P.; Jenkins, Jessica N.; Stewart, William C.

doi:10.1016/j.ophtha.2004.08.022

Cited by 93 publications

(58 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This study also evaluated the effects of three PG analogues at night, for which little information exists. 14 We documented the immediate 24-h IOP response at 1 week, as well as the longer term comparisons (1 and 3 months) with these three medications.…”

Section: Discussionmentioning

confidence: 99%

24-h IOP control with latanoprost, travoprost, and bimatoprost in subjects with exfoliation syndrome and ocular hypertension

Hepşen

Özkaya

2006

Eye

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

24-h IOP control with latanoprost, travoprost, and bimatoprost in subjects with exfoliation syndrome and ocular hypertension

Hepşen

Özkaya

2006

Eye

View full text Add to dashboard Cite

“…[6][7][8][9][10][11][12] All patients signed an Institutional Review Board approved informed consent form before enrollment. Previously treated patients underwent an untreated washout period comprising 4 weeks for brimonidine, or dorzolamide; 5 weeks for beta-blockers or the dorzolamide/timolol fixed combination; and 6 weeks for prostaglandin analogues.…”

Section: Methodsmentioning

confidence: 99%

Twenty-four-hour efficacy of the brimonidine/timolol fixed combination versus therapy with the unfixed components

Konstas

Katsimpris

Kaltsos

et al. 2007

Eye

View full text Add to dashboard Cite

Purpose To evaluate the 24-h intraocular pressure (IOP) control of brimonidine/timolol fixed combination (BTFC) versus the unfixed combination of its individual components, each dosed twice daily, in patients with primary open-angle glaucoma or ocular hypertension. Methods An observer-masked, randomized, crossover, active-controlled, two-centre comparison. Following a 6-week medicine-free period, patients were randomized to BTFC or to the unfixed combination of brimonidine and timolol for 3 months. Patients then were crossed over to the opposite treatment for another 3 months. At the end of the medicinefree period, and each treatment period, patients underwent 24-h IOP measurements at 0600, 1000, 1400, 1800, 2200, and 0200 hours. Results Twenty-eight patients completed this study. Both BTFC and the unfixed components showed a significant IOP reduction from untreated baseline (Po0.0001), and were statistically equal when compared directly, for each individual time point and for the 24-h IOP curve (P40.05). The mean 24-h IOP was 24.671.9 for baseline, 19.271.9 for BTFC, and 19.271.6 mmHg for the unfixed components (P ¼ 1.0). Four patients were discontinued due to side effects. The most common ocular adverse event was ocular hyperaemia (n ¼ 3 with BTFC and n ¼ 5 with the unfixed components, P ¼ 0.7) and systemic adverse events were rare. Conclusion This study suggests that both BTFC and the unfixed components of brimonidine and timolol provide a significant 24-h IOP reduction from untreated baseline, and statistically equal control when compared directly, at each time point and for the 24-h pressure curve.

show abstract

“…2003; Konstas et al. 2005). Thus, we consider that the combination of different PGAs will not cause heterogeneity in the network meta‐analysis.…”

Section: Limitationsmentioning

confidence: 99%

Efficacy and safety of different regimens for primary open‐angle glaucoma or ocular hypertension: a systematic review and network meta‐analysis

Huang

Zhang

2017

Acta Ophthalmologica

View full text Add to dashboard Cite

PurposeTo assess the efficacy and safety of different regimens, including monotherapy and double therapy, for primary open‐angle glaucoma (POAG) or ocular hypertension.MethodsWe searched PubMed, EMBASE and clinicaltrials.gov for studies that fit our inclusion criteria in this network meta‐analysis. Randomized controlled trials that report data on efficacy and safety of medications for POAG or ocular hypertension are included. Data on intra‐ocular pressure (IOP) lowering effect and incidence of adverse events including hyperaemia and ocular discomfort were extracted and used in mixed‐comparison analysis.ResultsThis study includes 72 randomized trials. Data were available on 12 medical treatments of POAG or ocular hypertension. Of 66 possible comparisons of outcome efficacy, 15 treatments were compared directly. Compared to prostaglandin analogues (PGA), beta‐blockers (BB) showed relatively weaker ability to lower IOP, followed by α2‐adrenergic agonists (AA) and carbonic anhydrase inhibitors (CAI). For dual therapy, regimens composed of a combination of PGA with another treatment demonstrated more powerful IOP lowering efficacy, while the combination of two non‐PGA drugs had lower efficacy in controlling IOP than PGA alone. There was no statistical significance in combinations that did not include PGA on efficacy of IOP control. In terms of tolerance, PGA alone leads to more severe hyperaemia than any other monotherapy regimen, while BBs have the lowest effect on the incidence of hyperaemia. Most dual therapy regimens containing PGA also lead to serious hyperaemia, with the exception of PGA + AA. Compared to regimens containing PGA, those with BB are less likely to cause hyperaemia.ConclusionOur network meta‐analysis showed that PGAs provide best IOP lowering effect among all the monotherapy regimen. Combination of PGA and other category of drugs leads to better IOP decrease. Combination of BB and another non‐PGA drug may have less ocular side‐effects than PGA alone.

show abstract

Latanoprost 0.005% versus bimatoprost 0.03% in primary open-angle glaucoma patients

Cited by 93 publications

References 29 publications

24-h IOP control with latanoprost, travoprost, and bimatoprost in subjects with exfoliation syndrome and ocular hypertension

24-h IOP control with latanoprost, travoprost, and bimatoprost in subjects with exfoliation syndrome and ocular hypertension

Twenty-four-hour efficacy of the brimonidine/timolol fixed combination versus therapy with the unfixed components

Efficacy and safety of different regimens for primary open‐angle glaucoma or ocular hypertension: a systematic review and network meta‐analysis

Contact Info

Product

Resources

About